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SUMMARY OF RECOMMENDATIONS
The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians screen all sexually active women, including those who are pregnant, for gonorrhea infection if they are at increased risk for 
infection (that is, if they are young or have other individual or population 
risk factors; see Clinical Considerations for further discussion of risk fac-
tors). B recommendation.
Women with asymptomatic gonorrhea infection have high morbidity due to pelvic 
infl ammatory disease, ectopic pregnancy, and chronic pelvic pain. Pregnant women 
with gonorrhea infection are at risk for preterm rupture of membranes, preterm labor, and 
chorio amnionitis. There is fair evidence that screening tests can accurately detect gonor-
rhea infection and good evience that antibiotics can cure gonorrhea infection. There is fair 
evidence that screening pregnant women at high risk for gonorrhea, including women at 
high risk because of younger age, may prevent other complications associated with gono-
coccal infection during pregnancy, such as preterm delivery and chorioamnionitis. Potential 
harms of screening and treatment for gonorrhea include false-positive test results, anxiety, 
and unnecessary antibiotic use. There is insuffi cient evidence (due to a lack of studies) to 
quantify the magnitude of these potential harms. The USPSTF judges the magnitide of the 
potential harms to be small. The USPSTF concludes that the benefi ts of screening women 
at increased risk for gonorrhea infection outweigh the potential harms. 
The USPSTF found insuffi cient evidence to recommend for or against 
routine screening for gonorrhea infection in men at increased risk for 
infection (see Clinical Considerations for discussion of risk factors). 
I recommendation.
The morbidity from undiagnosed and untreated genital gonorrhea infection is lower in 
men than in women. Clinical symptoms are more likely to lead to diagnosis and treatment 
in men; thus, the prevalence of asymptomatic infection in men is lower. There is fair evidence 
that noninvasive screening tests can accurately detect gonorrhea infection and good evi-
dence that antibiotics cure gonorrhea infection. Potential harms of screening and treatment 
for gonorrhea include false-positive test results, anxiety, and unnecessary antibiotic use. 
There is insuffi cient evidence (due to a lack of studies) to quantify the magnitude of these 
potential harms. The USPSTF judges the magnitide of the potential harms of screening men 
for gonorrhea to be small. Given the low prevalence of asymptomatic infection in men, the 
USPSTF could not determine the balance of benefi ts and harms of screening for gonorrhea 
infection in men at increased risk for infection. 
The USPSTF recommends against routine screening for gonorrhea 
infection in men and women who are at low risk for infection (see Clinical 
Considerations for discussion of risk factors). D recommendation.
There is a low prevalence of gonorrhea infection in the general population and con-
sequently a low yield from screening. Thus, the USPSTF concludes that potential harms 
of screening (ie, false-positive test results and labeling) in low-prevalence populations out-
weigh the benefi ts.
The USPSTF found insuffi cient evidence to recommend for or against 
routine screening for gonorrhea infection in pregnant women who are not 
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at increased risk for infection (see Clinical Consider-
ations for discussion of risk factors). I recommendation.
The prevalence of gonorrhea infection in pregnant women who 
are not at increased risk for infection is low. The USPSTF could 
not determine the balance between benefi ts and harms of screening 
for gonorrhea in pregnant women who are not at increased risk for 
infection.
The USPSTF strongly recommends prophylactic 
ocular topical medication for all newborns against gono-
coccal ophthalmia neonatorum. A recommendation.
There is good evidence that blindness due to gonococcal oph-
thalmia neonatorum has become rare in the United States since the 
implementation of universal preventive medication of infants. 
CLINICAL CONSIDERATIONS
• Women and men under the age of 25 years—
including sexually active adolescents—are at highest 
risk for genital gonorrhea infection. Risk factors for 
gonorrhea include a history of previous gonorrhea 
infection, other sexually transmitted infections, new or 
multiple sexual partners, inconsistent condom use, sex 
work, and drug use. Risk factors for pregnant women 
are the same as for nonpregnant women. Prevalence of 
gonorrhea infection varies widely among communities 
and patient populations. African Americans and men 
who have sex with men have a higher prevalence of 
infection than the general population in many commu-
nities and settings. 
• Individual risk depends on the local epidemiology 
of disease. Local public health authorities provide guid-
ance to clinicians to help identify populations who are 
at increased risk in their communities. In communities 
with a high prevalence of gonorrhea, broader screen-
ing of sexually active young people may be warranted, 
especially in settings serving individuals who are at 
increased risk. Additionally, clinicians may want to 
consider other population-based risk factors, including 
residence in urban communities and communities with 
high rates of poverty, when making screening deci-
sions. Low community prevalence of gonorrhea infec-
tion may justify more targeted screening.
• Screening is recommended at the fi rst prenatal 
visit for pregnant women who are in a high-risk group 
for gonorrhea infection. For pregnant patients who are 
at continued risk, and for those who acquire a new risk 
factor, a second screening should be conducted during 
the third trimester. The optimal interval for screening 
in the nonpregnant population is not known.
• Vaginal culture remains an accurate screening test 
when transport conditions are suitable. Newer screen-
ing tests, including nucleic acid amplifi cation tests and 
nucleic acid hybridization tests, have demonstrated 
improved sensitivity and comparable specifi city when 
compared with cervical culture. Some newer tests can 
be used with urine and vaginal swabs, which enables 
screening when a pelvic examination is not performed.
• Appropriate treatment of gonorrhea infection 
and administration of prophylactic medication to 
newborns have been outlined by the Centers for Dis-
ease Control and Prevention (CDC) (http://www.cdc.
gov/std/treatment/42002TG.htm#Gonococcal). Genital 
infection in men and women may be treated with a 
third-generation cephalosporin or fl uoroquinolone, and 
pregnant women may be treated with third-generation 
cephalosporins. Because of emerging fl uoroquinolone 
resistance, the CDC issued new treatment guidelines 
in 2004 recommending that men who have sex with 
men and those who acquired an infection in California, 
Hawaii, or Asia not be treated with fl uoroquinolone 
antibiotics. If clinicians have not concurrently screened 
for chlamydial infection, the CDC recommends 
presumptive treatment for chlamydia at the time of 
treatment for gonorrhea. In order to prevent recurrent 
transmission, partners of infected individuals should be 
tested and treated if infected, or treated presumptively.
• Gonorrhea is a nationally reportable condition. 
More complete reporting of gonorrhea cases to public 
health authorities will permit more accurate estimations 
of gonorrhea prevalence. Improved information will 
allow clinicians to screen for gonorrhea in ways that 
improve the balance between benefi ts and harms for 
their patients. 
• Research priorities for gonorrhea screening 
include greater understanding of the benefi ts of screen-
ing men at increased risk, especially men who have sex 
with men, and the role of reporting on gonorrhea rates 
and testing priorities. 
• See other USPSTF recommendations on screen-
ing for sexually transmitted infections (chlamydial 
infection, hepatitis B and C virus infection, HIV, geni-
tal herpes simplex, and syphilis) at http://www.ahrq.
gov/clinic/cps3dix.htm#infectious. 
DISCUSSION
Infection because of Neisseria gonorrhoeae remains the 
second most common reportable disease in the United 
States, the fi rst being Chlamydia trachomatis. In women, 
gonorrhea is a major cause of cervicitis and pelvic 
infl ammatory disease. Pelvic infl ammatory disease, in 
turn, can lead to ectopic pregnancy, infertility, and 
chronic pelvic pain. Gonorrhea in pregnancy is associ-
ated with adverse outcomes, including chorioamnio-
nitis, premature rupture of membranes, and preterm 
labor. Perinatal transmission to infants can cause severe 
conjunctivitis resulting in blindness if untreated and, 
rarely, sepsis with associated meningitis, endocarditis, 
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or arthritis. In men, gonorrhea can result in symptom-
atic urethritis, epididymitis, and prostatitis.1 Emerging 
evidence suggests gonococcal infection facilitates sus-
ceptibility to and transmission of HIV in both men and 
women.2
In 2003, the rate of reported gonorrhea in the 
United States was 116.2 cases per a population of 
100,000. With decreasing rates each year since 1999, 
this marks the lowest rate of gonorrhea ever reported 
by the CDC. Nonetheless, only 8 states had gonorrhea 
rates below the Healthy People 2010 national target of 
19 cases per a population of 100,000. The prevalence 
of gonorrhea varies widely among regions of the coun-
try, with the South reporting the highest rates (149.8 
cases per 100,000 in 2003). Rates in the South, how-
ever, have been decreasing steadily since 1999, while 
rates in the West have been increasing. Both rates and 
changes in rates differ among racial and ethnic groups. 
Reported cases are rising among whites and Hispan-
ics, and decreasing among African Americans. The rate 
among African Americans (655.8 per 100,000 popula-
tion), however, still remains 20 times higher than for 
whites. As in past years, the rate of gonorrhea reported 
in 2003 remains highest among women aged 15 to 24 
years and men aged 20 to 24 years.3 
While assessing individual risk factors provides 
valuable information to help determine whom to 
screen, clinicians should carefully consider the local 
epidemiology of gonorrhea infection in developing 
screening programs. National, state, and county-level 
sexually transmitted infection surveillance data are sum-
marized by the CDC annually. Clinicians may wish to 
consult with their local health departments to obtain 
information more relevant to their specifi c communities 
and practices. 
The USPSTF examined evidence published from 
1996 to 2004 to determine the effi cacy of gonorrhea 
screening in decreasing gonorrhea-related morbidity and 
mortality in the general population, those at increased 
risk, and pregnant women. In addition, the USPSTF 
reviewed the literature for new evidence concerning the 
harms of prophylactic medication to prevent gonococcal 
ophthalmia neonatorum. While including key questions 
concerning individual risk factors, this review did not 
include a full review of issues surrounding screening for 
gonorrhea infection in men who have sex with men. 
Issues that were not fully reviewed include choice of 
test for screening at rectal and pharyngeal sites and the 
potential role of screening for gonorrhea in reducing 
transmission of HIV. Although the gonorrhea prevalence 
outside of HIV care settings among men who have sex 
with men has not been widely studied, other groups 
have developed more specifi c recommendations for men 
who have sex with men.1,4 
Screening for genital gonorrhea infection can be 
accomplished using culture, nucleic acid amplifi cation 
tests, and nucleic acid hybridization tests (nucleic acid 
probes). Culture isolates can be collected from endo-
cervical swabs in women and urethral swabs in men. 
Culture specimen specifi city is 100% when culture 
isolates are speciated to differentiate Neisseria gonorrhoeae 
from other organisms (because most studies defi ne cul-
ture as the gold standard); however, the sensitivity of 
culture varies widely, ranging from 61.8% to 92.6%, but 
remains high when transport conditions are suitable. 
Sensitivity for nucleic acid amplifi cation tests ranges 
from 66.7% to 100%, with specifi city ranging from 
93.9% to 100%. Nucleic acid amplifi cation tests may be 
used with urine specimens in addition to endocervical 
and urethral swabs, and single specimens can be used to 
test for chlamydia as well as gonorrhea. Vaginal swabs 
may also be used with certain nucleic acid amplifi ca-
tion tests. Nucleic acid probes have reported sensitivity 
ranging from 54% to 100%, with specifi city ranging 
from 96.8% to 100%. Nucleic acid probes may also be 
used to test for gonorrhea and chlamydia in a single 
specimen and may be stored for up to 7 days without 
refrigeration.5 Overall, newer tests have demonstrated 
sensitivity and specifi city comparable to cervical culture, 
and compare better when transport conditions are not 
suitable for culture. Nucleic acid amplifi cation tests can 
be used with urine and vaginal swabs, which enable 
screening when a pelvic examination is not performed. 
Nucleic acid amplifi cation tests, however, have lower 
sensitivity when performed using a urine specimen. 
Antibiotic therapy is highly effective in eliminating 
urogential Neisseria gonorrhoeae infections. Recommended 
treatment for uncomplicated urogenital gonococcal 
infections from the CDC include one of the following 
antibiotic regimens: cefi xime, 400 mg orally in a single 
dose; ceftriaxone, 125 mg intramuscularly in a single 
dose; ciprofl oxacin, 500 mg orally in a single dose; 
ofl oxacin, 400 mg orally in a single dose; or levofl oxa-
cin, 250 mg orally in a single dose.1 Pregnant women 
should be treated with a cephalosporin-based regimen. 
Because of increased prevalence of resistant organisms, 
fl uoroquinolones should not be used to treat men who 
have sex with men and patients whose infections were 
acquired in California, Hawaii, Asia, or other areas with 
increased resistance to fl uorquinolones.6 To prevent 
gonococcal ophthalmia neonatorum, a prophylactic 
agent should be instilled into the eyes of all newborn 
infants; this procedure is required by law in most states. 
Prophylactic regimens include a single application of 
silver nitrate (1%) aqueous solution, erythromycin 
(0.5%) ophthalmic ointment, or tetracycline ophthal-
mic ointment (1%),1 all of which are effective. 
No study has directly examined the harms of 
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screening or treatment for gonorrhea infection. Poten-
tial harms of screening may include opportunity costs 
to the clinician and patient (time, resources, etc) and 
false-positive test results that may lead to stress, label-
ing, and further testing. Even using a test with a speci-
fi city of 99% in a population at high risk for gonorrhea 
with a prevalence of 0.5%, two thirds of positive 
screening tests would be expected to be false-positive 
results. Harms of treatment include adverse drug-
related effects.
In addition to research on the potential harms of 
screening, research is needed to provide direct evi-
dence that screening is associated with improved health 
outcomes. Specifi cally, studies are needed to evaluate 
screening criteria for men, including men who have 
sex with men, and pregnant and nonpregnant women. 
Additional research is needed to determine optimal 
screening intervals for these populations as well as for 
screening after treatment. High-quality cost-effec-
tiveness studies of current clinical options, including 
screening criteria and types of diagnostic tests, will also 
help inform future gonorrhea screening programs.
RECOMMENDATIONS OF OTHER GROUPS
The American Academy of Family Physicians (AAFP) 
and the American College of Obstetricians and Gyne-
cologists (ACOG) recommend screening sexually 
active women, including adolescents, at high risk for 
gonorrhea.7,8 The AAFP, ACOG, and the American 
Academy of Pediatrics (AAP) recommend screening 
pregnant women at risk for gonorrhea.7,9 The Depart-
ment of Defense recommends screening for gonor-
rhea in all pregnant women based on a presumption 
of potential risk within their system.10 The AAFP and 
AAP recommend routine prophylaxis for newborns 
against gonococcal ophthalmia neonatorum.7,11 The 
Centers for Disease Control and Prevention (CDC) 
has published recommendations on diagnostic testing 
for gonorrhea that support the use of culture as a test 
for use when screening.12 The CDC also recommends 
that clinicians consider all positive screening tests pre-
sumptive evidence of infection and consider additional 
testing when screening in low-prevalence populations.12 
In its 2002 Clinical Treatment Guidelines, the CDC 
recommends that all sexually active men who have sex 
with men be screened at least annually for genital gon-
orrhea and also for pharyngeal and rectal infection if at 
risk due to exposure.1 The Infectious Disease Society of 
America recommends that all HIV-positive individuals 
be screened for gonorrhea.4 
This statement summarizes the U.S. Preventive 
Services Task Force (USPSTF) recommendation on 
screening for gonorrhea and the supporting scientifi c 
evidence, and updates the 1996 recommendations con-
tained in the Guide to Clinical Preventive Services, second edi-
tion.13 Explanations of the ratings and of the strength of 
overall evidence are given in Appendix A and Appendix 
B, respectively. The complete information on which 
this statement is based, including evidence tables and 
references, is included in the evidence synthesis5 on this 
topic, available through the USPSTF Web site (http://
www.preventiveservices.ahrq.gov). The recommenda-
tion is also posted on the Web site of the National 
Guideline Clearinghouse™ (http://www.guideline.gov). 
Recommendations made by the USPSTF are inde-
pendent of the U.S. Government. They should not be 
construed as an offi cial position of AHRQ or the U.S. 
Department of Health and Human Services.
APPENDIX A
U.S. Preventive Services Task Force Recommendations and Ratings
The Task Force grades its recommendations according to one of 5 
classifi cations (A, B, C, D, I) refl ecting the strength of evidence and 
magnitude of net benefi t (benefi ts minus harms):
A.  The USPSTF strongly recommends that clinicians provide [the 
service] to eligible patients. The USPSTF found good evidence that 
[the service] improves important health outcomes and concludes 
that benefi ts substantially outweigh harms.
B.   The USPSTF recommends that clinicians provide [the service] to 
eligible patients. The USPSTF found at least fair evidence that [the 
service] improves important health outcomes and concludes that 
benefi ts outweigh harms.
C.   The USPSTF makes no recommendation for or against routine 
provision of [the service]. The USPSTF found at least fair evidence 
that [the service] can improve health outcomes but concludes that 
the balance of benefi ts and harms is too close to justify a general 
recommendation.
D.  The USPSTF recommends against routinely providing [the service] 
to asymptomatic patients. The USPSTF found at least fair evidence 
that [the service] is ineffective or that harms outweigh benefi ts.
I.   The USPSTF concludes that the evidence is insuffi cient to recom-
mend for or against routinely providing [the service]. Evidence 
that [the service] is effective is lacking, of poor quality, or confl ict-
ing, and the balance of benefi ts and harms cannot be determined.
APPENDIX B
U.S. Preventive Services Task Force Strength of Overall Evidence
The USPSTF grades the quality of the overall evidence for a service 
on a 3-point scale (good, fair, poor):
Good
Evidence includes consistent results from well-designed, well-con-
ducted studies in representative populations that directly assess 
effects on health outcomes.
Fair
Evidence is suffi cient to determine effects on health outcomes, but 
the strength of the evidence is limited by the number, quality, or 
consistency of the individual studies, generalizability to routine 
practice, or indirect nature of the evidence on health outcomes.
Poor
Evidence is insuffi cient to assess the effects on health outcomes 
because of limited number or power of studies, important fl aws in 
their design or conduct, gaps in the chain of evidence, or lack of 
information on important health outcomes.
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To read or post commentaries in response to this article, see it 
online at http://www.annfammed.org/cgi/content/full/3/3/263.
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